ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Upgraded by Leerink Partnrs

ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They set an “outperform” rating and a $80.00 price objective on the stock. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Down 4.4 %

Shares of NASDAQ ANIP opened at $56.56 on Wednesday. ANI Pharmaceuticals has a 12-month low of $51.24 and a 12-month high of $70.81. The company has a market capitalization of $1.19 billion, a PE ratio of -102.84 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm’s 50-day moving average is $58.04 and its two-hundred day moving average is $60.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. Equities analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,731 shares of company stock valued at $2,015,861. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in ANIP. Innealta Capital LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth $65,000. Ridgewood Investments LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $85,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $207,000. Finally, HighTower Advisors LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $222,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.